Good afternoon and welcome to the weekly market update with me, David Madden. Today's date is Monday the 17th of August 2020 and the time has just gone 12-12 for the summertime and it's been a fairly quiet start to the European trading session even though we've seen volatility is fairly low but we are seeing modest gains being shown across European stock markets even though there isn't a whole lot to be optimistic about. It's the same old stories. The coronavirus crisis is still very much at the forefront of traders minds. Sadly we're seeing some countries in Europe and Asia either reimpose stricter restrictions or at the very least express concerns about their respective health crisis. US-China relations continue to be defrosty. The trade talks that were supposed to go ahead were cancelled. This is going to add to the kind of sour relationship between the two largest economies in the world. On top of that, speaking of the US and politics there is still no deal reached between the Republicans and the Democrats in relation to having a stimulus package. So these are all the kind of major topics and themes of the week of the session. Like I said you know we are still pushing a small bit higher despite the fact that there isn't a whole lot to be cheery about. What I'll do is I'll start off by looking at the week ahead article which can be found on our website cmcmarkers.com under insights and you go to news and analysis. A number of companies are posting their figures tomorrow. We've quoted numbers out from Walmart, Home Depot, Nvidia. We first have numbers from person in the home builder. On Wednesday we have the minutes from the latest Fed meeting. On Thursday we have the closely watched US jobless claims. The city world were supposed to report their numbers this week but they pushed them back until late September. We have a third quarter update from Deer & Co on Friday. Also on Friday we have UK public finances. We'll see what the borrowing of the British government has now arrived at. We also have an update from the UK in terms of retail sales. And lastly we have the flash PMI reports for France, Germany and the UK. So that's going to give an indication of manufacturing and service reports from some of the largest economies in Europe. I'll start off by taking a look at the FTSE 200. For those of you who tune in regularly it'll be to these videos. It'll be the usual rundown. I'll cover a few of the big industries. I'll cover a couple of big currency pairs. And then I'll take a look at a couple of commodities. So the wider upward trend for the last few months remains intact. You know we're talking that the lows for March now remains intact. But notice how in the last few weeks the highs of July failed to take out the highs of June. The lows in July took out the lows in June. And then we had a rally in the middle of August which the rally in August didn't really, didn't didn't retest the highs of July. So we're seeing to be a bit range bound. And if anything the culture below the fifth of the moving average is blue line here. It seems to be a slight bias to the downside. And should we remain below the fifth of the moving average, we could see further losses from here. It should not be the case. We can head back down towards the psychology important 6,000 Merck. And if you go below that, we can be looking at retesting the lows of the lows of late July into early August. And they come into play in around 5,852. And if you go below that, the kind of 5,800 will be the next big number to watch out for. But if you do manage to press on higher from here, and if you take out the highs of August, we could be looking at retesting this zone here in around 3,443,000 sorry apologies, 6,340 this area here. They're there about active resistance and number of occasions in the past. So it's likely to be a significant level if you get back up there again. That's what's going on on the FTSE. I take a look at what's going on over in Germany. So as you can see here on the DAX solid upper trend for the last few months, similar to it, you know, what's a bit different between the DAX and the FTSE 100 is the lows of late of late July didn't really actually take out the lows of June. So we're still in the kind of upper upper trend, even more so on the DAX. Fair enough, the highs of August have yet to take out the highs of July, but we're still in the upper trend. We're comfortably above this blue line here, the fifthly moving average. And while we continue to hold above that, it's likely we could see the wider uptrend continue. If you press on higher from here, we could be looking at targeting 13,000 is a big psychological number. Should we go beyond that, we could then be looking at retesting the highs of July. And if you go beyond that, we could then be looking at heading back up to levels last seen in February. I moved to the downside might find some support from this blue line here, the fifthly moving average. And that comes to the play just north of 12,600. And if you go below that, we could be heading back down towards the lows of early August in around there. There are about 12,500. And if you have a, you know, quite a large move to the downside, we could even head back down towards the lows of late July. This blue red line here, the turning moving average acted nicely as support back then. That comes in the play just north of 12,200. And if a metric has been important in the past, it makes it more likely it'll be important in the future, although there are no guarantees. Take a look now what's going on. The Dow Jones. The Dow Jones is in pretty good shape. To be honest, I think it's been quite boring. If you look at the range, the last few sessions have been fairly low, it's been pretty much range bound, but the wider upward trend over the last few months is very much in play. If you press on higher from here, we could be looking at retesting the highs of last week. And that's in around 28,155. Also keep on this level here, 28,164. Coming back from the lows of late January. And of course, if you take off this level here, the highs of August, we could then be looking at targeting back up to levels last seen in late January, just as a kind of crisis was really taken hold in the US. Any moves to the downside on the on the Dow Jones could find some support in this zone here in around 27,633. We have been quite, you know, we have been short in a tight range last few months, last few weeks rather. So if we do break below that, we could be heading back down toward this zone here down around 27,000. We can see that there there are about active support at the beginning of the month. And there are a few occasions in July when well just north of 27,000 active at resistance. Turning our attention to the strongest index of the bunch, the S&P 500, which is not too far away from its all time high, which is incredible if you think about it, given what's going on with the US economy. But nonetheless, you know, even though there isn't a deal that has not been struck between the US and the Democrats in relation to a stimulus package, some people, you know, some tears have a view out there that some sort of an agreement will be reached at some point. So the S&P 500 continues to be in a strong upper trend. If you press on higher from here, we could be looking at retesting the highs, the all time highs that are posted in mid February. And if you go beyond that, the next big kind of big number to look out for will be 3,400. Any pollbacks could find support back down toward this zone here down around 3,326. And if you go below that, we could be looking at any back down toward this area here in around, in well, in around 3,300 itself. And then below that down toward this zone here in around 3,280.  So if we do see a pollback that we could see some fresh buyers enter the fold. That concludes the indices section. I'll start off now on the currency starting up at Eurodollar. So is the Eurodollar here? It's been a nice upward trend that the last few weeks been in a very positive trend recently. Only in early, only a while ago, we were hit, the Eurodollar hit its highest level in over two years. So it's in a strong upward trend. We traded at its side range bound the last few sessions, but we're still nonetheless in the upward trend. If you press on higher from here, we could be looking at retesting the early, the early August highs in around here, just what comes into play north of 119 in around 11916 there, thereabouts. And if you go beyond that, you know, the kind of psychology important one spot 20 will be the next level to keep an eye out on. Any move to the downside could find support in on the recent lows. Because of the lowest low of August has been in around one spot 16, 96, this area here, but we can see just north of that metric. There's a few occasions that that area well above that mark acted as support. If you go over all that down towards one spot 16 could act as support as well. And it's only really if you prefer a large pullback, could we head potentially back towards this blue line here, the fifth movie average, that's quite a way away. Notice how it acted nicely as support back in May. So if you have a decent size support, decent size pullback, we could be heading back down towards that level. The pound is also in pretty good shape given the weakness in the US dollar. So we can see here, it wasn't that long ago, the pond was at its highest level since early, early March. So multi month highs have been achieved not too long ago, even though we've kind of had a pullback and we kind of, we kind of rebounded it up in the pullback. We're still very much in the wider upward trend of the last few months. So if you press on higher from here, we first could be re testing the highs of early August. And if you go beyond that, we could be looking at heading towards you kind of 132. And if you go beyond 132, we could be looking at targeting this metric here one spot 32, 84, the highs of late December. Any moves, any pullbacks in the pound versus your daughter might find support from this zone here in around 130. It's kind of a big number. We're currently at one spot 30, 78, 79. And of course, if you imagine you have a decent move below 130, we could be looking at heading back all day down towards kind of 128, big consolidation for the 120 area there. It also acted as a resistance. Well, just north of the resistance in early June. And if you go below that, we could be looking at heading towards this, this area here where the red line, the turn to moving average kind of runs into, runs into the 50 moving average. So common important metrics converging on each other. And that comes in the play one at one spot 2712. Take a look now what's going on on the gold market gold and obviously a lot of volatility recently. At the beginning of the month, an all time high had a major pullback major move to the downside last week, but note the the long wick on this candle here on when to the 12th denotes indecision. And what do you know? The market has been recovering somewhat since then it's only claw back a portion of the ground at last. But nonetheless, why we can hold above the 1900 mark, it's likely we could see the wider upper trend continue. Should that be the case? 2000 is a big psychological number. If we go beyond 2000, we can then be looking at retesting the high, the recent highs, which are posted earlier this month. If we do have a move to the downside, if you go below 1900, this this every you know, some traders will be keeping an eye off of this area in at once at 1863, the recent lows here for money from last week. And if you go below that, we could be like heading down towards just below it, the 50 moving average, this blue line here in at one spot, sorry, 1844. Notice how it acted nicely as support. Back in the middle of middle June, like I said before, of a metric has been important in the past, it makes it more likely it'll be of importance in the future, although there are no guarantees. And lastly, I take a look at Brent crude oil, the October contract. To be honest, it's been fairly boring the oil market recently. It's tied in with the kind of perception about the global economy. It's good, good barometer for how, you know, economies are reopening, so potential for increased demand. But on the flip side, you know, if economies are going to be re closing, that could occur potential demand. So the last few sessions, it's been fairly range bound, but the wider upward trend is the very much in play. If we do press on higher from here, we could be like heading up towards 46 bucks, or just north of that, that the recent highs in a 46 by 23. And if you go beyond that, we could be looking at targeting the lows of early March in at once 46 spot 67. Any new to the downside, you can find support from the zone here in around 44 spot 24. And the move below that could take us back down towards this blue line here, the 50 day moving average, which comes into play pretty much just right on 43 bucks. That's all from this week. Thank you for listening. Stay safe and have a good training week.


up a topic I want to talk about FDA. I want to talk about the FDA the right to try right to try by the way allows patients who are dying only if they're dying to use experimental FDA drugs it still requires a whole process and it's still cumbersome and difficult and nowhere near as easy as it should be but it's better than it was before and Trump gets credit for that but that does bring up the FDA and the FDA just put up this week new standards for the production of home kits for testing for COVID. You'll be able to test at home you'll be able to get results within minutes rather than within days or weeks it'll be easy no pinprick no but all at home everything will happen at home and they are companies that wanted to offer this a couple of months ago and the FDA stopped it now they've actually put out a plan the criteria for what they would approve in terms of home kits and from what I've seen the companies are basically saying you're insane with these kind of requirements it'll never be profitable never be commercial never be possible for us to produce the kits that'll happen sometime next year maybe I mean the idea would be ideally to lower the cost to about a dollar test a dollar test and it is possible but the FDA wants these to be too good something can be too good for example if you make the test kit super super accurate so it can test very low viral loads that would be wow that would be amazing but that would be really expensive and very difficult to put in a home kit even the commercial kits that out there have a hard time doing it but you could make a pretty cheap one that only detected very high viral loads but when are you when are you when can you infect other people now when you have a low viral load when you have a high viral load so why not give people the option of testing themselves and when they have a high viral load they would know not to go out not direct with other people isolate themselves low viral load with social distancing and all that no big deal things like that things that have to do with logic and common sense and taking account how people use something and some you know the kind of logic and common sense that markets produce the kind of products that markets create that don't have to be perfect by the standard of some central planner but a good enough good enough so we're probably not going to get home kits again we probably could have had them two months ago we're probably not going to get home kits because of the FDA and of course this is just one minor concern I have with the FDA you know the FDA even with the now right to try law the FDA is responsible for the deaths of thousands of hundreds of thousands of potentially millions of people every year because of the cost that it loads up on drugs it makes it so difficult to produce now look somebody would have to have to be some screening of drugs they wouldn't just go to market you would have to test them and screen them and so on and doctors wouldn't prescribe drugs unless they were tested and so on but imagine if that were done in a competitive market imagine the cost savings and also imagine if people had the option not just dying people but all people had the option of evaluating the risks that they were willing to take instead of just saying oh no it causes in 10% of patients it causes heart disease drug x patient being able to say but you know what it helps so much my other problems that I'm willing to take the risk of higher of heart disease that 10% of patients incur and another patient would say you know what that risk of heart disease really really scares me I'm not willing to take it imagine putting the decision on a doctor and a patient on individuals rather than on a bureaucratic entity that has all all the wrong incentives now I don't believe that it would be drug companies selling directly to doctors and they would I truly believe there would be a privatized a private equivalent to the FDA because you don't want a situation in which one rogue drug company and you do want standards of testing but I think the standard of the testing would be determined competitively there would be labs to test drugs that would do the equivalent of phase one phase two phase three testing some of it would done by the company and somebody would some of them would be done by the labs the labs would then review the results presented it to it the labs get presented to them they would evaluate it they would review it they would test it and they would give doctors a rating of how what they think this drug is good for what they think the risks are and they will let doctors decide and labs might even give the drug an F and they would let doctors know it's got an F I wouldn't use it and my guess is that doctors would pay for the service rather than drug companies because doctors are the ones that have the strongest incentive to have accurate information about the drugs that they are prescribing to their patients and you could imagine a whole insurance liability structure that would make this function in a way that did not create negative incentives but that requires imagination and that you know that's the beauty of free markets is they do these things these things are created entrepreneurs come up with ideas they build they create they produce the FDA is just an obstacle for all of that a one-size-fits-all bureaucratic nightmarish institution that basically not just does it make drug development super expensive but it makes some drugs just not worth the while of companies to produce because of the risk that they're not get approved and because of the cost involved I mean I think the same would happen with food with a lot of things you'd have middle men who would work for the grocery stores inspecting the agricultural produce that they were buying rather than a government agency and probably wouldn't be something super marketed themselves I think you'd have a whole field a whole industry develop there would basically a private sector industry who would replace what the FDA does today what we need today what I called a new intellectual would be any man or woman who is willing to think meaning any man or woman who knows that man's life must be guided by reason by the intellect not by feelings wishes women's or mystic revelations any man or woman who values his life and who does not want to give in to today's cult of the spare cynicism and impotence and does not intend to give up the world to the dark ages and to the role of the collectivist right before we go on reminder please like the show we've got 163 live listeners right now 30 likes that should be at least 100 I figure at least 100 of you actually like the show maybe they're like 60 of the Matthews out there who hate it but but at least the people who like it you know I want to see I want to see a thumbs up there you go start liking it I want to see that go to 100 all it takes is a click of a click of a thing whether you're looking at this and and you know the likes matter it's not an issue of my ego it's an issue of the algorithm the more you like something the more the algorithm likes it so you know and if you don't like the show give it a thumbs down let's see your actual views being reflected in the likes but if you like it don't just sit there help get the show promoted of course you should also share and you can support the show at your own book show dot com slash support on patreon or subscribe star or locals and and show your support for all for for the work for the value hopefully you're receiving from this and and of course don't forget if you're not a subscriber even if you even if you just come here to troll or even if you're here like Matthew to defend marks then you should subscribe because that way you'll know when to show up you'll know what shows are on when they're on you'll get notified right so yes like share subscribe support like share subscribe support there you go easy do one know all of those please


Hello and welcome to the session. In this session we discussed the following question which says for what values of P are the points 2, 1, P minus 1 and minus 1, 3, collinear. For the given points A with coordinates x1, y1, B with coordinates x2, y2, C with coordinates x3, y3, area of triangle A, B, C formed by the points A, B and C is given by half into x1 into y2 minus y3 plus x2 into y3 minus y1 plus x3 into y1 minus y2. This is the key idea for this question. Now let's move on to the solution for this question. We consider the point A with coordinates 2, 1, B with coordinates p minus 1 and C with coordinates minus 1, 3. Now since it's given that the points A, B and C are collinear, so the area of the triangle formed by them must be 0. First we find out the area of triangle A, B, C. Now this is equal to half into x1 that is 2 into y2 minus y3 that is minus 1 minus 3 plus x2 that is p into y3 minus y1 that is 3 minus 1 plus x3 that is minus 1 into y1 that is 1 minus y2 that is minus 1. This is further equal to half into 2 into minus 4 plus p into 2 plus minus 1 into 2 that is this is equal to half into minus 8 plus 2p minus 2 that is this further is equal to half into 2p minus 10. So we get area of triangle A, B, C is equal to p minus 5. Since we have already discussed that the area of the triangle formed by the points A, B and C must be 0. So we have p minus 5 equal to 0 gives p equal to 5. Now let's do the verification. So now the points are A with coordinates 2, 1, B with coordinates 5 minus 1 and C with coordinates minus 1, 3. So the area of triangle A, B, C is equal to half into x1 into y2 minus y3 plus x2 into y3 minus y1 plus x3 into y1 minus y2 that is this is equal to half into 2 into minus 4 plus 5 into 2 plus minus 1 into 2 that is this is equal to half into minus 8 plus 10 minus 2 which further is equal to half into 10 minus 10. So this comes out to be equal to 0. So we have got area of triangle A, B, C is 0 thus p equal to 5 is correct. Thus the final answer is for p equal to 5 the points 2, 1, p minus 1, minus 1, 3 are collinear. So this completes the session. Hope you have understood the solution for this question.


What's up everyone? It's your girl Kenty here from Leighton Sports Guards and I'm going to put a personal here for Jake S. We've got a 2022 Topps Gilded Collection baseball hobby. All right Jake, best of luck. Here we go. Gilded love this. I'll have to go grab the boxes, bro.  I don't know if I've ever seen a redemption. Definitely not. It's definitely a redemption. It's got more air in it than anything. It could be a good sign. It could be a good sign. Like I said, I've never seen a redemption than that before. Empty. All right, right Dean, this is such a beautiful product. We've got a Honus Wagner Pirates. Honus Wagner, 63 of 99. That's a mini diamond here of Matt Olson. That one is 10 out of 50. Raves Matt Olson. First auto up. We've got a Whitmerefield. Whitmerefield on the black frame 95 of 99. Black edge. Next one out. We've got Dolphins and Joey Wendell. Joey Wendell, Marlon 65 of 99. And last one here, we've got Wayrave Rookie of Romy Gonzalez for the White Sox. 25 of 25 bookends. All right, again redemption here. Have yet to see a redemption out of this. Empty. Good luck. Goldframed Hall of Famer autograph. Pedro Martinez for the Red Sox. You were right, Chris. Pedro Martinez, Red Sox. All right, that'll do it for your box. Jay, congrats on those hits. Such a beautiful product and fun rip for you. Thanks again. We'll get these right out to you.


It's an honour and a pleasure to be here. I should perhaps explain my status a bit more. I'm at the pre-university of Amsterdam one day a week and the remainder of the week I'm at the Dutch competition authority and officially I'm wearing my Amsterdam hat here today so this is all academic although I will draw time and again I think on experiences at the competition authority. What I do there I'm in the health care division and in a practical sense over the past few years I've been working mainly on pharmaceuticals both on cases which I think I'm not going to name today because there are no public decisions in those yet. We also provide guidance for example we have provided guidelines on collective purchasing of pharmaceuticals and in an attempt to create counter-failing market power there and we've also conducted a sector inquiry into TNF alpha inhibitors which is a class of drugs that are used to fight rheumatism. My talk has been over the long and tight and I thought at first this was the fault of the organiser but when I checked again it turns out this was actually the talk the title of the paper that I wrote together with my colleagues Kies van Zijn and Elon Ucker. So I can't blame the organisers and it's not really a research paper that has been distributed in the materials but it's largely practical and I'll try to explain why we ended up writing it. What it tries to do is something new in that we have already discussed there's such a thing as applying the competition rules to companies that hold intellectual property rights. What we haven't discussed much today but what also exists is applying the rules on excessive pricing to pharmaceuticals and what we wanted to do in this paper is combine them both. So to say you can apply the rules on excessive pricing to patent protected or otherwise benefiting from exclusivity rights undertakings. I'm going to first discuss briefly the Dutch context because I've elatedly realised that you're not fully familiar with that. I will say something then about the EU antitrust rules and intellectual property but some of it has already been discussed today and I'm not going to run in any detail through the case law. I will then say something more about what I assume you're the most interested in which is how would you go about dealing with excessive pricing in this context. I will then say something about other remedies in case our excessive pricing cases fail and or otherwise in the broader context and if there is time I will say a few words about compulsory licensing at the end of a reserve a sliding reserve for that we'll have to see if there's time for that. So the Dutch context is very different from the UK. Our system is not a national health service but it's insurance-based also sometimes called this mark system which I'm not sure is wholly appropriate but that's what people call it anyway sometimes and you have a beverage system by the way. It's insurance-based it's fully private so both the health insurers are all fully private all health care providers are private companies and in addition we have a system where drugs that have a market authorization automatically qualify for reimbursement if they use this part of a hospital treatment so there are no prior negotiations or anything they just enter the market and can claim their reimbursement so perhaps this is already explains a little bit why we have problems with higher prices in the Dutch context. So the first point is that why we start looking at this is that we feel we have a problem with pharmaceutical pricing in the Netherlands it's certainly a political problem it's something that plays out in the media a lot and we see weekly discussions of this both in the newspapers and on television so it's something that has political attention and although we are an independent authority that also means that it has the attention of the competition authority. I realize I'm already slipping into we from being the university for university of Amsterdam so pharmaceuticals are also a problem because it's they account for a growing share of annual health care costs and the way I've written down the figures here probably doesn't allow you to make much sense of them but the idea is basically that pharmaceuticals account for about 10% of the hospital budget they're growing at 10% a year so that means they're adding a percent percentage point every year and that's at a time when we're trying to reduce growth of hospital care funding from 1% to 0 over the course of coming years and that means that effectively pharmaceutical products are displacing other forms of care now you could have different opinions on whether that's a good thing or a bad thing but it's definitely something to think about and we like to think of it as that there is at least a risk of them crowding out other forms of treatment that are equally valid the different types of pricing problems there's repurposing of existing drugs where there has been limited or new research with significant price hikes I think we've heard some of those instances mentioned here some of them problems are with extremely priced new patented and orphaned drugs some of which are sometimes repurposed as well and then as an order of magnitude you have to think about drugs that might be 100 000 euros per patient per year or more going up into the 800 000 euros and higher still there also is another category of drugs and the tnf alpha inhibitors are within that category that's expensive drugs that are not at far side outrageously expensive because they're only between 10 and 20 000 euros per patient per year but there are so many patients that suffer from rheumatism that's high volume in effort for that reason a problem and in addition and more recently we didn't think we'd have a problem with low prices but we're also looking at anti-competitive discounts as well in order to where we think that originator companies may be trying to keep biosimilar drugs for example in the area of tnf alpha inhibitors out of the market there have been some attempts to address this by means of regulation government intervention there's a general price gap that we have which is based on external reference pricing but it's generally considered to be ineffective because it's based on the list prices in a number of neighboring countries including the uk and those are not actually the prices that anyone pays so as a price cap it's not very stringent because it doesn't take account of the discounts that are applied in practice we have only limited centralized price negotiations about which i'll say a little bit more later on it doesn't play a very important role because we have those competing health insurers who in principle have to negotiate themselves and sometimes they manage in the area of outpatients so non-hospital treatments they're selected purchasing by the health insurers and generally they managed to get a fairly good deal but it doesn't really work that way for intramural so hospital treatment patients various things have been tried there a system of add-on pricing which means the hospital bills separately for the medications so at least the insurers know what the price tag is which is already something we have tried as an authority the competition authorities try to promote more collective purchasing by indicating what scope there is for that within the competition rules if anyone is interested we can discuss that perhaps separately and on the menu for today's what we're trying to do is pursue a more active competition policy and the question is to what extent that would be compatible with intellectual property rights so essentially i think i already gave the gateway right at the beginning there is simply parallel application of the intellectual property and competition rules that's not something that we started out with when we wrote the paper because we wanted to look at past pharmaceuticals and ran into a lot of opposition from strangely enough especially economists both within an outsider organization who are pointing towards things like innovation and also insisting that the highest value imaginable is that of property and here you're combining both so you couldn't possibly want to infringe on that by applying the competition rules so they basically framed intellectual property rights as an absolute bar to antitrust i think that's a question mark but and even the place there any more in view of what we've already discussed today at the same time we also encountered a very cautious approach by the EU antitrust authorities i think i'm not disclosing any secrets when i'm saying there's an ongoing dialogue between the different authorities at the different levels and the EU doesn't always at the community level lead the way in every aspect sometimes they're more comfortable taking a backseat and following on at a later stage and perhaps a more impressive scale i think what we ended up setting out in the paper is perhaps not that innovative at all what we essentially said was the intellectual property rights and competition rules apply in parallel going back to the constant case one of the early competition cases where it was held that intellectual property rights should not be used to frustrate the cartel prohibition there's a directive on intellectual property rights enforcing which although only in a recital clearly states this does not prejudge the application of the competition rules on the other hand it's also clear that patent is not always a relevant market so therefore it doesn't always imply a dominant position let alone abuse of a dominant position and what we're effectively working towards and if we look at EU competition law and industrial and intellectual property is a coexistence of the relevant principles i'm not going to run through the case law in detail but what we've seen is several phases initially there was case law to do with with blocking parallel trade parallel imports and there was ruled that the existence of an intellectual property right doesn't mean there is firstly dominance at the same time even the exercise of intellectual property right may constitute abuse and using or abusing the patent system as we've also heard today can form an abuse so these are just some general principles that confirm that coincidence coexistence and this phase which is more to my mind about exclusion is rounded off with the pay for delay case as i'm citing here lundberg survey and the recent generics case where essentially it was held that restrictive agreements are possible even within the scope of a patent and that generics are potential competitors which is an important principle that was confirmed at the highest level in the generics or peroxidine case which is an interesting case in many aspects also because it emphasized that anti-competitive effects should be balanced against proven pro-competitive effects which i think is one of the the most interesting aspects of the case but from the perspective of a competition authority it's a very welcome case i'm sure the cma will be very happy with it as well because it seems to confirm that as we've heard this morning from chris stothers as well um essentially pay for delay is not um something you should do and is something that can clearly be caught by the competition rules now for something slightly more controversial so far it's been about exclusion so keeping competitors out of the market and then the other half of competition law at least conceptually if not in practice is exploitation countering exploitation and there the question arises what is a fair price that's the the the way that advocate general neils vile started his opinion akala case asking that question eventually he did see scope for a methodology to determine such a fair price but it's something that's rarely done and that's very difficult so competition laws are preference for enforcing the provision on exclusion for several reasons one is a practical one competition authorities like to stay out of price regulation because it's messy and they don't have the resources to do it more ideologically you would say that you would prefer markets to fix themselves so if you manage to fight exclusion effectively then that will take care of the exploitation because there will be market entry and excess profits will be competed away as we've also heard this morning and that would then be a market fixing itself and anyway what is an unfair price and how do you determine it it's a very complicated question whether there's very little guidance available so far at the same time at the national level there's already been a move away from the bay for delay cases to excessive pricing cases and these are cases where the exploitative abuse of off-paston drugs primarily was prosecuted we've seen the aspen case in italy confirmed that the highest judicial level visor flinnabout which we've heard today where we'll get interesting news on monday there's cd pharma in the uk which i believe has been confirmed that the highest judicial level there and on the back of this the e-competition has started its own aspen case essentially in all EU member states except italy and therefore crossing an important bridge for european competition law enforcement where the convention itself now is willing to prosecute excessive prices so far this is all fairly established practice although you could debate about what exactly the standard would be for an off-paston drug but clearly where there is very little innovation involved and apart from the intellectual property more procedural aspects there's there for no reason to be particularly respectful of the product involved this is a different matter when you move into intellectual property right protected and orphan drugs well a few words about that our approach or the approach that we've taken in the paper and are trying to develop also other competition authorities how to approach a fair price is essentially by taking the incentives to innovate into account so that is the key to reconciling competition law and intellectual property law and that can take a practical that obviously has to take a practical aspect there's there are two phases to an excessive pricing proof in the first place you have to look at at the the margin and where this is excessive and you do this in a cost plus context and next you have to prove that the price is also unfair and this you do it based on comparisons with preferably products that are not just comparable but also in competitive markets so it provides it with a competitive benchmark and there are different degrees of complexity to this and what the competition appeals tribunal and Pfizer Flynn appears have done a set out of particularly demanding and complex tests in this respect and we're about to hear whether that is appropriate or not but in any event it is always going to be difficult because you have to look at the not just because you have to look at the figures but also because you have to find a meaningful comparator limiting ourselves ourselves to the intellectual property protected drugs here what we would propose is to take a life cycle approach so you look at the entire life cycle of the product and the degree of profitability at the various stages you should also look at the probability of success so you cannot assume ahead of time that that the product will will be a success but ideally what you need is what the company itself from an investor perspective thought that the likelihood was at which it was ready to invest in the product so what you look at is the investments in innovation in there then that also means there should be investments in innovation so it's not enough that something would be for example an orphan drug that in itself has improved that it's innovative if it's in a repurposed orphan drug it may well be that very limited innovation was involved in particular if it were to be a case where the same drug had already been used off license for several decades for the treatment for which it was subsequently awarded an orphan status and more technically and I hope there are no accountants in the room because I cannot withstand any serious degree of questioning on this but what you want to do is you want to compare the internal rate of return on the one hand within the company and then look at the weighted average cost of capital and compare those and essentially the next question becomes at what level would you then think an excessive price occurs and this is where the jury is very much still out are you looking at a multiple or are you looking at a percentage that's smaller than 100% and those are questions where the answers may well be different if you're talking about innovative IP protected under orphaned drugs rather than the off fattened drugs found for example part of the drug found in the Pfizer flim case might might be warranted to take it entirely different as standard into account so this I think is the core of the approach that we're proposing and unfortunately I can't give you any examples of successful application thereof although I can assure you that we're working on that and whether it would be successful or whether we'll ever be able to come out with results is an open question and in this context there are also other issues to do with market definition and dominance you have to look at the role of IP regulation in the context of market definition and dominance counterfeeling market power is an issue and then in the Dutch context in particular because we have to deal with the fragmentation on the side of the purchasers who are who are the health insurance companies as private undertakings other issues are whether off label use is part of the market and I think most people familiar with the EU case law and that would think that most likely this and pharmacy preparation is another life issue whether pharmacy preparations which can be relevant in particular to orphaned drugs whether very small patient populations whether that should be seen as a substitute to be taken into account in the context of market definition and dominance determination so that was the core of my presentation I want to just use the remaining time to say a little bit about other possible remedies and the context of the competition law intervention there's several things you might want to look into one is how to avoid over investment in social welfare terms where we found that in some cases drugs that are incredibly expensive in the order of magnitude of almost a million euros per added healthy life here there are actually sometimes pretty good arguments in terms of the underlying costs so we find out that you've got something that exceeds the quality threshold so that is the amount that you would normally be willing to pay for an added healthy life here which in the Netherlands is 80 000 euros and we've found drugs costing 800 000 euros which means that they're displacing for every healthy life here added there displacing nine healthy life here somewhere else but nevertheless justifiable in terms of cost although not perhaps in terms of social welfare so that's something you want to look at and more in general the role of health technology assessment and the role of qualities and ICERS are relevant there I don't think they probably should be a price cap nor should they be used necessarily as the standard for willingness to pay but they can provide a comparison across different products that may be useful if you are doing comparisons also in an excessive pricing context public pricing intervention is something that is perhaps less relevant here in the UK than it would be in the Netherlands I'm not entirely sure what the system here is but I think you've got more control over products entering the markets and negotiating a price before they do if we're going to keep external reference pricing we probably wanted to be purchasing power parity based and also we may want it to be based on actual prices paid if available rather than on list prices that nobody's actually ever paid manage entry agreements are something that essentially involves only allowing a product onto the market after you've agreed a pricing arrangement at the gate and horizon scanning is another mechanism that you want to introduce where you know well ahead of time what's going to happen when the products are coming onto the market and you can account for the budget implications of that finally promoting competition for the market is something to look at tendering promoting tendering preferential sourcing and joint purchasing initiatives is something that our competition authority has looked at has looked at and tried to promote that with the health insurance companies unfortunately we have to say that so far the our results are fairly discouraging you can do that at a national scale or internationally there's a Benelux initiatives of the Benelux countries Austria and Ireland I think Canada has either joined or is thinking of joining to start negotiating at an international level well unfortunately it seems that so far this is merely aspirational and hasn't actually led to too many boots on the ground yet and final a final point here is that what we found out when we evaluated our our joint purchasing guidelines or guidance is that effective switching appears to be much more enforced than volume so it's not that helpful to organize on a large scale and because it's more difficult to reach consensus on which products than to target but if you're even on as a single hospital able to effectively switch your population between suppliers that may be much more effective at the end of the day than having a large volume that is more difficult to move but I'm happy to discuss maybe after the session with anyone who is interested in this kind of thing so finally a few words on on regulation also relevant to the Dutch context I think we need to adjust our regulation we need to close some regulatory loopholes and gaps with advocated revising the orphan regime which has basically got two possible ways of entry one is based on prevalence if you are rare disease and the other is based on profitability if you think you couldn't reasonably make a profit and it seems obvious and almost a drafting error that those are not cumulative requirements but our alternatives to my knowledge nobody's ever chosen the alternative route of saying that they couldn't be profitable which I think in itself is already indicative and that's also the reason that they haven't dropped out of the system after six months because nobody entered it on that basis health technology methods could be standardised at a level even though the cutoff or thresholds would probably have to be national in addition you could open some regulatory loopholes instead of closing them one of them is promoting pharmacy preparation or something that's happened in the Netherlands and to some extent pharmacy preparations are now becoming an alternative to some of the more expensive orphan drugs whether or not that's something that you would want to see in the long run is open for debate but it's definitely a regulatory loophole that can put some pressure on the industry compulsory licensing could be considered also as a competition remedy I don't think I have time for that but I have an additional slide on that that we can discuss maybe later also after the session what it also means is that if application of the competition rules in particular on excessive pricing doesn't work doesn't mean that that's the end of the game it means that we may be moving into things that nobody would really want but that are perhaps necessary in order to create a more level playing field where it's possible to negotiate a new more balanced outcome so we need a more effective competition enforcement which means developing a framework to take innovation into account about which I've just spoken I think we should at least try to enforce the rules whether we're going to win our case or not in the end at least we have to try developing in the process experience and a certain track record in doing so and experience has taught me that failing as at enforcing the competition rules sometimes means that you will by finding what you wanted being introduced by means of regulation now whether more regulation is always the solution is the question if we could solve it based on just the competition rules that might be preferable and of course there is always room for academic contributions and I think we could shed in particular more light on the balance between innovation access and affordability between IP rights and competition principles as I've just tried to do a little bit then there's an issue of balancing competition and regulation that I've just touched on very lightly and also as somebody mentioned Bill and Melinda Gates already alternative funding methods might be something to study whether it would be in terms of competitions or prizes or dealing with publicly funded innovation in different ways an open question and I think I'm not going to start with the compulsory licensing so I'll wrap it up here and thank you for your attention


Breaking news the Indianapolis Colts announced before we went live three hours ago, and that's how big news it is. Yep Nick Foles will be starting for the Indianapolis Colts on Monday night football against Cameron Dicker Justin Herbert, Kyle Van Noy and the Los Angeles Chargers. Hell, yeah big Nick is coming to town just two days after old St. Nick comes through to everybody's. I didn't I didn't figure the Colts were good I didn't figure they were an organization that tanks We're not thinking it's a Super Bowl MVP the guys got a statue outside of a stadium


Right guys, how we doing back with another video the 67th best player in the NFL for the year of 2022 Buddha Baker the man who was chased down from behind by well Call him Godzilla call him Jaws the great white shark. I don't know what he was but he was on a mission and he clawed him down Right at the last second. All right. We're not talking about DK. He's most probably gonna be hopefully, you know On the list in the top 50 either way. We've got Buddha Baker number 67 He's a safety for the Cardinals and he plays like an absolute beast He reminds me of Tara Matthew, you know, they're pretty much on par as far as size as far as tenacity and You know all of that and more will be revealed So let's get into it Whoops Buddha Baker is a heat-seeking missile and he's upended by Buddha. Oh, yeah, he's a 15 He's a player. He's a bullet. He's a blur out there He just does everything in a hundred miles an hour. If Buddha Baker doesn't make that play Jermart might have still been running shoots Ex question is later cut down by Buddha I'll tell you what there's got to be a point. It doesn't matter how many million dollars per year you you earn Or you're about to get paid. There's got to be a point where you have to sort of think is it worth it? Is it worth shooting first and worrying about your? health later Well, he hasn't got to that point yet When he hits, I mean he lays into you and I think he walks around at 180 soaking wet, but he's a hell of a player Am I the only guy that whenever they see Chandler Jones on the screen the first thing that comes to mind is John Jones I think Buddha Baker a man. He's one of the most explosive players in the league.  He got dressed up for the interview. It was such reckless abandon Oh He's a force he comes out of that center field and he's down for horrible. He's trying to take absolute look There's look look I'm gonna I'm gonna say this right here right now He's certainly got he must have had over a hundred concussions in the league thus far.   No, there's only one way to survive Buddha Baker You know, we've got the Buddha rule How do you survive Buddha Baker? What is the Buddha rule?  He's gonna be around the ball It's to no hesitation because you'll see him 15 yards deep and then he'll make the tackle at five yards I like Buddha Baker. Just watch how much ground he covers on this one play and talk us through it. I Don't even have to see this place to know how much ground he covers He's like a missile Yeah Literally how many get like that's a game of five the man who actually tackled him was about 20 yards deep Let's have a look at this. I don't even have to see this place. All right. The line of scrimmage is on light What the 24? Okay, quarter back rolls out. Thanks for the running back. Okay someone is Okay, so the line of scrimmage was at the 20 really and talk us through it Can't we have to see this place? No, it's not how much ground he covers So at this moment, he's on the 15 20, so there's 20 yards between the quarterback and Buddha Baker right now He's like a it's a pass into the flat. There's still you know, look we'll say what 18 yards between the receiver and the tackler And just like that in a split second, there's five yards taken off Buddha Baker is Coming in hot I'll say that much and so to think To think he stops him at The 21 the 20 yeah, they lost yards They lost yards and Buddha Baker was over 20 yards back in the in the in the backfield You know, you know a couple of seconds earlier, that's that's some real He's coming oh brah what a play what's this? He's there to wipe you out He has no fear when he's coming down. He's he's oh man that play just gets better and better ready because if you're not is It's gonna hurt. I mean you have something coming and he gets so low to the ground he's so aggressive and he just kind of flies to that shin area and There's not really much you can do there just takes you out like knee down and that's the most efficient way to tackle somebody Look, it might be the most efficient But it's certainly not the safest, but that's Buddha Baker for you. He attacks everything 100% full speed He's just a fantastic tackler. I've seen him.  He's turning that recklessness into pics Just work that he puts out there you see on tape never takes place off never he's got a 4 4 40 I dash I'll give him that much What was it 4 4 3? What was it 4 5 6? I guess you never really know a 4 4 5 No idea 32 and a half inch vertical 9 foot 7 on the Broad jump 14 on the Wonderlick. It's not the best. It's not the worst, but Bench press the 15 reps he is 5 foot 10. I'm gonna call it 5 foot 9 195 pounds went to Washington Through college got picked up in the 2017 draft round to pick number 36 to the Cardinals been there ever since He's a four-time pro bowler and his rocky season had a year out 2019 2020 and 2021 And the man is just all over the field In four, sorry five seasons. He's had 539 combined tackles Wow 27 passes deflected five interceptions including three last year, which is his career high five force fumbles Five Fumber recoveries and one recovered for a touchdown Let's have a look at his last deal I did mention this last year, but we'll go into it again August 25th 2020 he signed a four-year 59 million dollar contract extension with the Cardinals Making him the highest paid safety in the NFL in NFL history at the time I'm assuming someone has eclipsed that Which is unbelievable in itself loves his boys around the football He's good at his hands.  He's always in the right place at the right time It's awesome. I mean buddha is one of my favorite players in the league I just feel like I'm gonna be honest man the more times I see these guys, um, the more times I think that uh Cooper cup and George Kittle Could be twins regardless of that Uh, that probably means nothing to you. Those are just observations. I've made through watching 33 of these videos thus far or is it 34 could quit. I think it's 34. Anyways guys. Look, thank you for watching um, thank you for Riding with me thus far and uh, and the next one we're looking at the man with the biggest hands in the entire NFL almost 12 inches, which believe de Forrest Buckner. Cheers guys, and I'll see you then peace


So we're here with a candor and hello hi, so who are you the failure my client and founder of candor health products Can you introduce and I'm with my co-worker. I eat your guide and my other young co-worker And what are you showing here? What is the proper sector? It's our personal toothbrush holder what it does it protects from airborne contaminants as well As the prevention of bacterial growth on the toothbrush The way it does that is through the ventilation system. That's turned on by the sensor at the top And after 30 minutes it shuts off automatically So it does ventilation system. Yes, sir. So it's like cools down the Bacteria can't begin to grow on the brush because that's horrible. Everybody has these wet toothbrushes Yes, and it's a wet continually because you use the first thing every day in the morning And it just continues to say moist and moist and what the next time you use the toothbrush. It feels like new So where's the power battery it's rechargeable battery Can you can you open it up and show I can't open it, but I can show you the USB right there Yes, so it's easy to charge has a chargeable rechargeable battery that lasts about seven to ten days Is this for sale? It is not on the market yet, but we're looking to come out for the consumer around April and where you based Houston, Texas Texas. So is it Texas invention? Is it your invention? Yeah, your invention. It's my invention. All right. We got an issued utility pad on this product and 2013 what did you do before do you have other projects? No, I'm a former postal employee Oh, yeah. Yes, I used to work for the postal service. I worked out most 25 years. Nice. So what's gonna be the retail price? They basic retail price of being 2495 for the basic model and the ones with the Wi-Fi and the blue team 3995 and does it prove them to work? Well, yes We test them already Not scientific, but we just test them in office and I would also eliminate all the bacterias with like The reason why we're not doing UVA and UVB laser is because we wanted to make it kid-friendly And so we didn't want to take a risk of burning anybody's eyes and we wanted to transparent not All right So distributors welcome to contact and make a big order


Well, hello and welcome to Understand Men Now. I'm Jonathan Asley of jothanasley.com, and I'm so excited to be shooting this short video for you today. Our topic, a surprising way a man will chase you. Surprising way a man will chase you. All right, wait, what's the topic? Yeah, you have to say this. I forgot to add that, you have to say this. Okay, really quickly, if you're new to my YouTube channel, please hit the subscribe button, hit the bell, so you can be notified of new content. I shoot about three or four videos per week. All right, you gotta say this. This is to get a guy to chase you.  That's the idea of the whole feminine energy leaning back is he's gonna naturally gravitate to fill that space if he really likes you. Okay, but here's the reality with most men. Most men have childhood wounds and traumas or adult traumas that cause them to be fearful of love. And if they're chasing love, it's because there's a deficiency inside of them. There's a deficiency inside of them. And in addition, men are territorial. So men can chase you because we might treat you like property, there I spit, okay? But that's not healthy. Men who treat you like property, men who are territorial, that's not healthy. That might have a short-term benefit, but this doesn't have long-term benefits. And I want you to begin to, by the way, have my shirt really quickly. This is, I'm shooting this video early, but this is gonna be posted on New Year's Eve. So I thought I'd wear a festive shirt for New Year's Eve. Okay, hopefully I'll be going, I don't know what I'll be doing for New Year's Eve.  Okay, so, but I wanna lean back, go back. Oh God, I totally lost my train of thought. What's going on here? All right, let's just try to bring it back altogether. So emotionally unhealthy people will chase love. Yes, they chase love. Or they're chasing sex, okay? They're either chasing love or chasing, they're chasing love from an unhealthy place, or they're chasing sex for a temporary fulfillment in their lives. But I want you to actually begin choosing a higher quality kind of guy, that kind of guy that wants to, who's ready for a fully committed relationship. And this is one of the reasons why I teach what I call vetting men, vetting men. This is how to vet for emotional maturity, okay? And if you need some support on that, check out my link to a free discovery call. My area of expertise is teaching you how to identify emotionally mature men. Because emotionally mature men will invest in you. Let's take out the word chase and let's replace it with invest with you. And he's investing it with you, it's in a two lane street.  And if you make an investment, he's gonna make an investment. And that's how it looks when you're in a healthy, juicy relationship. And I want you to say this next thing to help him make an investment in you. And this is certainly for the early stages of dating. In fact, this is literally the first or second day kind of words to make a man make an investment in you. And I'll never forget, I had a first date with a woman. This is some years back. And somewhere in the middle of the evening, she said to me, if you asked me out on a second date, I would say yes. I'm like, wow, that was kind of interesting. And I'm sure she heard that from someone else.  Well, later, as I reflected upon it, it felt contrived only because I'm a dating and relationship coach, I analyze everything. This is one of the reasons why I'm probably still single is I analyze everything. I've got to get out of my own head. My head is my problem, okay? For those wondering, why am I still single? It's this, I'm great at dishing out advice, but sometimes I have a hard time hearing my own advice. But what I loved and what she said was, she gave me a green light. She dropped the hanky. She gave me an invitation to move forward. And I want to take this to the next level. I want you to take this to the next level. And I want you to adopt some new language when you're communicating with men who you want to make an investment in, okay? So you've gone on one, two, or three dates. He seems to be pursuing you. And I want you to throw in this question or this statement, and it goes something like this. I would be open to exploring a relationship with you. I would be open to exploring a relationship with you. Would you be open to exploring a relationship with me? Now you followed up with the question. I'm open to exploring. No, so now it kind of puts them on the spot, but that's what you want. You want to put men on the spot from the perspective of either they face the reality because men who are just simply chasing love or men who are simply chasing sex, they're so hyper-focused in kind of a needy selfish way. And I want you to lean into men who are looking at it as a two-lane street as I talked about, okay? I'd be open to exploring a relationship with you. Would you be open to exploring a relationship with me? And then the follow-up question, and this is the most important thing you say, is what does a healthy, happy relationship look like for you? What does a healthy, happy relationship look like for you? This requires them to look inward. This is one of the reasons why I'm such a big proponent of self-love because people can't look inward, aren't loving on themselves. If a person can't love on themselves, it's gonna make it very difficult for them to explore a healthy, juicy, delicious relationship with you. This is why I always recommend my book What the Heck Is Self Love Anyway? I talk about this often, often, often. There's a link below to get my book, okay? I want you to start choosing those men who are gonna lean into it. What's a healthy relationship look like for you? And ladies, if you need some support on understanding what they look like, I talk about this in almost every one of my videos. Check out the book Eight Dates by Dr. John Gott, John and Julie Gottman.  They're clueless not because they don't care, it's because we haven't been taught. None of us have been taught this stuff and one of the things I hear from clients over and over and again. Jonathan, I wish people taught, I wish I learned this in high school, I wished I learned this in college, I wish my parents taught me this, I wished I learned this 10 years ago. That's what I'm here to support you on and I want you to start making a shift and say this to see if he's ready for a full commitment with you. Ah, okay, if you have a question or have any comments, please post it below. I do my best to read all of them and I'm gonna wrap up this video as I always do for my New Year's Eve shirt. Wishing, giving myself a big gigantic Jonathan Bear hug of self love, I'm gonna reach into the camera and give you a hug of love if that's okay. I'm gonna ask you to turn to someone or a pet or a teddy bear and give them a hug of love because hugs are a great source of love and we can all use more love in our lives. I wanna thank you so much and wishing you a super duper wonderful day. Bye-bye now.


And I'm actually surprised that they don't market this as a unisex fragrance. Hey, what's up guys? This is Josh here today. I want to do a little review on a fragrance called straight to heaven by the house of Killian. Now Killian's always been just a very high quality house. I haven't dived too deep into it. And I did smell a copy of straight to heaven from central obsessions. Now this was kind of in the beginning of central obsessions where he did very, very affordable oils. But at that time they were a little bit cheaper. Now he has kind of like the gold line, which is just much more tuned up. The original straight to heaven that I smelled, it was a little bit more raspy than this. This is a lot more smooth, a lot more high quality, which you'd expect from Killian. This DNA has always been one that I really, really like. The notes that they have online are Virginia cedar, patchouli, rum, dried fruits, nutmeg, musk, amber, vanilla and jasmine. Now, for some reason guys, this fragrance just really smells to me like a really high quality vanilla ood style fragrance. Now I know this fragrance doesn't have ood in it with maybe a little bit of spice in the background. Okay. This is the first time that I've ever smelled this rum note and all the times that I've sprayed it. And they actually sent me two samples of this one. I sprayed the whole first sample. This is my second one. This is the first time I've ever smelled the rum note, which is just keeping me out. This is definitely for somebody who's mature, but it's not the most serious fragrance. It definitely smells kind of good, a little bit sexy, a little bit likable. But at the same time, I really couldn't see somebody under 25 wearing this personally. I mean, you could wear whatever fragrance you want to wear, but I just don't see someone under 25 wearing this. It is likable and it is mature. I could just see this kind of being like an everyday kind of a scent for somebody older. It's got a likable vibe. It is mature. I guess you could wear it to work and you could wear it to play if you are someone of a mature person. That's just like where it fits to me. It's just a very noticeable scent, a likable scent. As far as the longevity and projection on this stuff, I get, I would say, medium to a slightly above average on this stuff. I probably give this probably a 7.5 to an 8 as far as longevity and projection. It's noticeable. It smells good, but for me, it wasn't beast mode. This is just a fragrance that I've really enjoyed. It's just a likable fragrance for somebody mature.  And to me, guys, like I said, it doesn't really smell like too many things. I'm just smelling that rum note right now, but normally it kind of smells like a complex oot and vanilla that I really, really like. I've always liked this DNA and I've always liked the name Straits Heaven. And I'm actually surprised that they don't market this as a unisex fragrance because I could see men wearing it, but I could also see females wearing it too. I think it could go either way personally. So anyways, guys, Straits Heaven, a really nice fragrance. If I were to give it a rating, I'd probably give like an 8 out of 10 for the smell. And like I was just saying, about a 7.5 to an 8 for longevity and projection. Likeability, I'd probably give it a solid 8. In certain situations, it's very, very, very likable, but at the same time for the younger crowd, I wouldn't think they would like it as much. So I think like an 8 seems fair. Overall, I really, really like this fragrance. And if you're somebody who's mature but also want something sexy, definitely pick this one up. I've always liked this fragrance and I will continue to like this fragrance straight to heaven. So anyways, guys, we're on the road of 50,000 subscribers and I couldn't do it without any of you guys to help. You guys are the best. Having a great day out here. Hopefully having a great day at home. See you all in the next video. Peace.


Hey there friends, thanks for checking in. This is going to be a CZ show-off video. I want to show my collection. I have eight CZs and we'll start right here with the CZ75 SP01. Steel frame full size handgun with 19 round megs. Excellent shooting handgun. This was CZ's darling 9 millimeter before the Shadow 2 and the TS2 and some of the higher end models and for good reason it's a it's a phenomenal handgun. Now it has rubber grips there. Many G10 options out there but I've stuck with the rubber grips. Sportward serrations, thumb safety that is ambidextrous and a single action trigger pull that measures right around four and a half pounds. Full rail right there. Night sights standard 4.6 inch barrel and a beauty of a handgun. Really enjoy this. It shoots incredibly accurate and I am going to just keep it. There's no reason to ever get rid of this model. Here is the newer CZ P10M. A lot of people were looking for a double stack subcompact 9 millimeter and CZ's yet to deliver that but many single stack fans still out there. It comes with two 7 round magazines. A 3.2 inch barrel. It's the P10 series so it's certainly reliable. The trigger pull, it does have a trigger tab in there, is a bit heavier closer to six and a half to seven pounds. Three dot sights. Overall pretty reliable. I like the forward serrations on there. The ergos are nice. Has some pretty heavy texturing but overall not bad for those who want deep concealment and they want to stick with CZ's and they don't mind the 7 round magazine that this P10M offers. Here is one of my favorites. The CZ 2075 Rami. CZ discontinued this. It's a mystery why they did that subcompact with a 3 inch barrel aluminum frame rubber grips.  It is just so accurate and nice. Single action trigger pull right around four and a half pounds. Love the CZ 2075 Rami. This is a BD model. Fire pin block and decocker puts the hammer in quarter cock but the Rami comes with a 14 round mag as well. I think I mentioned that but that offers a full three finger contact grip. It allows for even more accuracy and more capacity. Very nice option with this subcompact 9 millimeter. Here is the CZ 75 SP01 Phantom. They had this model out years ago then they dropped it then they brought it back for a couple years and then they dropped it again. So this is no longer available from CZ but it's identical to the SP01 steel frame except this has a polymer frame and it's a BD model. Okay firing pin block and decocker has the same 19 round magazines. It is much lighter. The uppers will interchange with each other so it's like shooting the steel frame model except that polymer frame makes it lighter. It has a full pick rail there. Same trigger pull. This does not have the night sights right around four and a half pounds. It does not have the night sights. Three dot sights right there but a great handgun and I'm happy to have it because they're hard to find. A little bit lighter. Love shooting this.  Six years ago CZ made their way into the polymer frame 9 millimeter handguns and they started out with the P10C and people called this a Glock Killer 15 round magazine. This has talon grips on there because the grip texturing on this is very heavy but they created a great handgun and what most people really love me included is the trigger pull. Check this out right around five and a quarter pounds but the reset is extremely short and audible.  A one slot rail there for attachments. Overall great handgun. A lot of people fell in love with it at the time. They had no idea that CZ would come out with a whole series of P10 models. This was the start of it. The CZ P10C still doing very well in the gun world. Here is another one of my favorites. It's the CZ 97 BD in 45 ACP. This basically mimics the Shadow 2 butt in 45 and I love it. So accurate. People told me about this. They said you have to check it out. I did. I fell in love with it and then I had to get one aluminum grips at our black 10 round magazines. It'd be nice if they could bump that up to 14 but this discontinued actually. It has a steel frame 4.65 inch barrel, two rear sights, fiber optic front sight, forward serrations. It also has a barrel bushing. It's screw in barrel bushing so that has to be removed when this is assembling the pistol. It has a loaded chamber indicator bar. Overall a phenomenal handgun. I love shooting this. 45 ACP. Excellent single action trigger pull. Double action. Very nice as well. I don't know why they discontinued it. I was kind of bummed but at the same time I'm very happy that I own one and plan to have this forever. In 2018 CZ introduced the CZ P10S. They expanded the P10 line with a shorter and lighter 9mm handgun and this has a 3.5 inch barrel 2 12 round magazines. I have an extension on there for 14 rounds but it's a P10C that's a little bit smaller and optic ready. It also has serrated black rear sights drift adjustable and a tritium front dot with an orange surround. A one-slot pick rail and the same trigger pull that is very nice. Very much impressed with the P10 series trigger pull and the trigger release, the reset. It's very very nice. Love shooting this. Once again I feel like I'm shooting a full-size handgun with the three-figure contact on that mag. The P10S take a look at their sight. They actually dropped the MSRP quite a bit with this model. This is one of CZ's darlings in the 9mm category and that is the Shadow 2. This is called the black and blue model. It has blue aluminum grips, a 4.9 inch barrel, all steel frame, beautiful handgun. They now make this optic ready. This one has serrated black rear sights, fiber optic front sight, a one-slot pick rail, hadjo sights. That's what they call those height adjustable only. Hadjo and ambidextrous thumb safety. A lot of people compete with this. The one thing I enjoy specifically is that single action trigger pulls around three and a quarter pounds and it offers one of the smoothest double action triggers that you'll ever see or feel. Here we have a 17 round mag. They offer three in the case, beautiful handgun overall and an amazing shooting handgun. You can't beat that single action trigger pull. I'd love to get the Shadow 2 that is optic ready. This one isn't but I'm certainly happy with it and have been since the day I acquired it. Those are my eight CZ handguns. I don't have all of them. I would love to have more but time and money plays a factor in this. But I would also love to have one in 40 but CZ does not make a 40 Smith and Weston handgun. So I've got one 45 and the rest are nine millimeters. I think they're all excellent handguns. You know the people on this channel, they love CZ. I love CZ and I just had to show these often. I certainly hope you enjoyed it. If you like videos like this, please subscribe and share. I always appreciate thumbs up button. Thanks for watching and you guys be safe.


Boy, anytime you get a clean sound that you can play, you know That's great Yeah, yeah, that's what you want to do right there is that Yeah, it's really good Man that is killer this sounds like creamy and smooth but clear great is it fun to play? Yeah


This is stock number 11144. We are here at Summit Automotive in Fond du Lac, Wisconsin. You're new and used heavy-duty trucks, headquarters. Today we are checking out this super clean, extremely low mileage 2016 GMC Sierra 3500 crew cab long box dual rear wheel. This truck has the 6 liter V8 motor. It has been fully safety and inspected by our service shop. Has a fresh oil and filter change. All the fluids have been checked and topped off. This truck is 100% ready to go. Only 4,000 some miles on this truck. Cardinal red is the color we shoot all of our videos in 1080p 60 frames per second. So if you have HD capabilities on your computer tablet or smartphone device, turn them on right now because it is definitely your best way to check out the quality and condition of the truck before seeing it in person. And if you'd like to check out all the photos on this truck in the upper right hand part of your screen is a link to our website, click that and check us out there. Steel rims are an excellent condition and it has Michelin LTX AT LT 235 80R 17 tires. These tires only have 4,000 miles on them. Frame and underbody is like new as you'd expect as well. This is a one owner clean title history, clean auto-check vehicle. You get the HID headlamps, the LED running lights. The front bumper is an exceptionally nice condition. No dents or dings on that. The headlight lenses are nice and clear and the grille is an excellent shape. The hood is in great condition as well. I didn't see any dents or dings on that. And the passenger side front fender is in excellent shape too. Passenger side rim, no scuffs or scrapes and as you go down this side of the truck, take note of how clean the body is, how reflective and mirror like that paint is. We take these HD videos so if you are far away or even if you're close by and you just cannot make the trip down, but you're still interested in purchasing the vehicle, you can see the vehicle, hear the vehicle and have confidence in what you were looking at before you even get here. So that when you do get here, there's no surprises. And that is why we offer the Summit Auto Fastpass option in the upper right hand part of your screen. A link right to our website where you can apply for financing, get pre-approved, see a payment quote, even appraise a trade, all from the comfort of your own home. So when you get here, all you got to do is drive the truck, love it, you'll be all set to go. Back tires are just as new as the front tires as you'd expect and look at that frame and underbody. I mean like new condition on this truck inside and out. Very, very nice and clean. Has all the remaining factory exhaust as you'd expect and of course the lower rockers all look really good. I didn't see any corrosion or anything on them. And as we come around to the back, the rear bumper is absolutely perfect as well. No dents or dings and that does have the rear bumper steps and the tailgate is in really nice condition as well. Locking tailgate, backup camera has a very nice spraying bed liner and it does come with the LED bed lighting up there. Shuts nice and solidly and as you go down the driver's side just as clean as that passenger's side. No dents or dings on this box side and for full disclosure this back rim is in excellent shape as well. Down the rest of the side of the truck looks really, really good. Does have the telescopic tow mirrors with the built-in directional signals. It also has the LED side lights. Those work with your cargo lamps. They also telescope out and in and fold in manually. Inside the work truck package gives you the gray cloth interior. There are no rips or tears on those seats. Does come with the 40-20-40 split bench seating. The heavy-duty rubber floors and the four-wheel drive shifter on the floor. Power windows, power locks and power mirrors. You do get auto headlamps and the factory brake controller right there. Turn the ignition on so you can see just how low miles this actually has. 4139 miles on this truck and the instrument cluster is very nice and clean. Steering wheel is in nice shape as well. You do get cruise controls on the left. The six-speed automatic transmission with the optional tap shift. This one comes with the GMC Intella Link system. You do get AM FM radio. You also get projections. So if you got a navigation system on your cell phone and you have Android Auto or Apple CarPlay you can project it to the screen and then you have the navigation up there. You do have your climate controls down here. Stability control and that's for your cargo lamps. That's how you turn on the lights in the bed as well as the lights on the mirrors. 4x4 shifter on the floor and the rest of the floor is absolutely perfect. Passengers side seat is in nice shape as well. No rips or tears on that. And the headliner is in really nice clean condition too. Up here you get your map lights and you do this button tells me that this one has the heavy or the snow plow prep package on this truck. You have your on-star capabilities in the mirror and we'll take a quick look at the back seats and then check out under the hood and start it up. Back seats are just as clean as the front seats. No rips or tears back here. It does have the latch child safety system for any child car seat needs you may have. That rear window does have the defrost in it and the seats are in nice shape back here. You do get a storage bin underneath them and the rubber floors back here look really good as well. We'll start it up and take a quick look under the hood. You can see those cargo lamps in the box as well as the LED side lights on the mirrors. They are super bright. Now we'll start up take a quick look under the hood. I would personally like to thank you for checking out the video today and hopefully from this HD video you'll have been able to tell just how clean this truck is all the way around inside. Now under the hood we have a 6.0 liter V8 motor and Jim Bay is very clean runs very smooth. This truck has been fully safe and inspected by our service shop as a fresh oil and filter change. All the fluids have been checked and topped off and this truck is 100% ready to go and here it runs really nice and smooth. Only 4,000 miles for the amazing truck. I would highly recommend it from a quality and condition standpoint and to see more pictures of this truck or one rather 450 new and used cars, trucks, SUVs, minivans, Wranglers, half tons, three-quarter tons, one tons, gas trucks, diesel trucks, you name it we got it. Go to our website www.summitauto.com full pictures and descriptions of every single vehicle from two locations all at summitauto.com and if you'd like to check out more HD videos you can go to youtube.com slash summit auto remember to like subscribe and share on this video and all the videos that you see there in fact any second you will see a link to subscribe to our youtube channel on your left a link to more GMC 3500 truck videos like this one on your right if you have not been on our website on the bottom link to this vehicle on our website click those check us out and we're super excited to be offering this extremely low mileage 2016 GMC Sierra 3500 crew cab longbox dual rear wheel with the 6 liter V8 in cardinal red thanks again for checking out the video.


A successful HIV vaccine should elicit broad adaptive and innate immune responses through prime boost platforms which are influenced by various factors such as antigen selection, vector type, delivery route, dose, adjuvant, boosting regimen, order of vector injection, and intervals between vaccinations. Heterologous may be better than homologous prime boost regimens for protection, with the most advanced strategies using canarypox or adenovirus vectors expressing mosaic antigens boosted by GP140 protein. DNA prime and vector protein boost regimens are at a less advanced stage of development but could contribute substantially to HIV epidemic control as part of a comprehensive prevention program. Post-efficacy activities are necessary for pumped vaccine access in populations with the greatest need. This article was authored by Jean-Louis Excler and Jerome H. Kim.


Howdy, thank you so much for coming. So would you please share with people and myself what was the thing that you struggled with? For many years or all my life. I've struggled with anemia and for those of you who don't know what that is that is having low iron in your blood and it causes like discoloration in your in your skin and I When I have when I had anemia I was very tired like I couldn't stay up during the day and I was in Activities at school, so I couldn't came up with my like my sport team or Like PE or any of that and I couldn't be I wasn't able to play with my nieces and nephews as much and um, I Also would get many many migraines like daily almost and Yeah Wow, that's pretty bad Now you said for how long did you have that sickness? 18 years for 18 years. Wow. That's a long time for a young girl for any person And so what happened? How did you receive your healing? I had to pray for my healing like several Sundays like when pastor Vlad would say put your hands like where it hurts I would put my hands on my wrist where my veins were and I would you know, I'd pray and I I would say I know I am healed in Jesus name and I didn't realize I was healed until I went to a doctor's appointment And I got some blood drawn and I asked oh, hey, can you check it from anemic? And so three days after they called me and they said that I was perfectly fine, and I had nothing wrong with me Oh, come on. Let's put our hands together for Jesus Christ That is a pure miracle and this is what God does and then and so Audi We're so happy for you for this miracle and healing that took place in your body Would you please share what of advice to people who might be struggling with sickness? And they want to receive that touch from God and receive their healing. What would you tell them? Sometimes healing can take a while or sometimes your healing can come instant But I just say don't lose your faith and don't lose hope in God. Amen. Amen. Thank you for watching this content I hope this was a blessing to you if you're like me and you like to click on things Click on this Subscribe to our channel and the content will come to you every time we post it and remember the best is yet to come